Protocolsβ€ΊImmune System Support Protocol
IntermediateImmune Support12 weeks

Immune System Support Protocol

Restore immune balance in immunocompromised or immunosenescent patients, reduce chronic infection susceptibility, and support cancer adjuvant care

Patient profile: Adults with frequent infections, post-viral fatigue syndromes (long COVID), immunosenescence (age > 60), or as adjuvant during cancer treatment

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’
⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

Thymosin Alpha-1

Primary

Dose

1.5 mg

Frequency

2x/week SC

Timing

Morning, consistent days (e.g., Mon/Thu)

Duration

12 weeks

LL-37 (Cathelicidin)

Supporting

Dose

100 mcg

Frequency

3x/week SC

Timing

Morning

Duration

Weeks 1–8, then reassess

Thymosin Beta-4 (TB-500)

Optional

Dose

1.5 mg

Frequency

1x/week SC

Timing

Any time

Duration

Weeks 1–12 (adjuvant tissue support)

Monitoring Parameters

  • βœ“Complete blood count with differential β€” baseline, week 6, week 12
  • βœ“NK cell activity (functional assay if available)
  • βœ“T-cell subset panel (CD4/CD8 ratio) β€” baseline and week 12
  • βœ“Inflammatory markers: hsCRP, IL-6, TNF-Ξ± β€” baseline, week 6, week 12
  • βœ“Infection log (frequency and severity of illnesses during protocol)
  • βœ“Fatigue score (FSS or MFI-20) β€” monthly

Expected Outcomes

1

Weeks 1–4: LL-37 antimicrobial action immediate; patients often report fewer acute infections

2

Weeks 4–8: T-cell proliferation increases, NK cell activity normalizing

3

Weeks 8–12: Sustained immune competence; fatigue scores typically improve by 40–60%

4

Post-protocol: Consider quarterly TA-1 maintenance (4 weeks on, 8 weeks off)

Contraindications

  • βœ—Autoimmune disease requiring systemic immunosuppression (relative β€” consult specialist)
  • βœ—Active solid organ transplant with rejection risk
  • βœ—Known hypersensitivity to any component
  • βœ—LL-37 should not be used in patients with active autoimmune skin conditions

Clinical Notes

Thymosin Alpha-1 is FDA-approved in Italy and China for hepatitis B β€” the strongest peptide evidence base for immune modulation. LL-37 bridges innate and adaptive immunity and has direct antiviral activity against enveloped viruses (including coronaviruses). This combination is evidence-informed for long COVID immune dysregulation.

Case Study

Clinical Practice Example

Female, 58, with long COVID β€” 18 months post-infection with persistent fatigue (FSS 48/63), recurring sinus infections every 4–6 weeks, and CD4/CD8 ratio 0.8 (inverted). Started TA-1 + LL-37. At week 6: no sinus infections, FSS improved to 34. At week 12: CD4/CD8 ratio normalized to 1.6, FSS 22. No infections in the following 6 months.

← Back to all protocols